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Abstract
Camel milk (CM) has been reported to have anti-diabetic properties in many in vitro
and in vivo studies but the molecular basis of such beneficial properties are still elusive.
Recently, camel milk whey proteins (CWPs) have been shown to positively affect the
activity of the human insulin receptor (hIR) in cell lines. In this study, we profiled
crude CWPs and their hydrolysates as well as camel milk lactoferrin (CMLF) for their
pharmacological and functional effects on hIR activity and its downstream signaling
in both human embryonic kidney (HEK293) and hepatocarcinoma (HepG2) cell lines.
For this, bioluminescence resonance energy transfer (BRET) technology was used to
assess hIR activity in live cells and the phosphorylation status of the downstream
protein kinase B (Akt) and the extracellular signal-regulated kinases (ERK1/2) was
also analyzed in parallel. Moreover, glucose uptake was examined in order to link our
data to more integrated cell response and to the hypoglycemic effects of camel milk.
Our data clearly demonstrate the biological activity of CWPs, their hydrolysates, and
CMLF, by promoting Akt and ERK1/2 phosphorylation in both HEK293 and HepG2
cells. In addition, our BRET assay confirmed the positive pharmacological action of
CWPs and their hydrolysates on hIR activity in a dose-dependent manner. More
interestingly, the combination of CWPs and their hydrolysates with insulin revealed
an allosteric modulation of hIR that was drastically abolished by the competitive hIRselective peptide antagonist S961. This clearly demonstrates the implication of hIR
activation in the effects of CWPs and their hydrolysates. Finally, such effects on BRET
data and kinase phosphorylation were clearly correlated with an increase in glucose
uptake in HepG2 cells. Our data reveal the pharmacological effects of camel milk
proteins on hIR activity and function. This provides for the first time the molecular
basis of the anti-diabetic properties of camel milk that was unknown until now.
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دراﺳﺔ ﺗﺄﺛﯿﺮ ﺑﺮوﺗﯿﻨﺎت ﺣﻠﯿﺐ اﻹﺑﻞ ﻋﻠﻰ وظﯿﻔﺔ ﻣﺴﺘﻘﺒﻼت ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦ
اﻟﻤﻠﺨﺺ

أظﮭﺮت ﻋﺪة دراﺳﺎت أن ﺣﻠﯿﺐ اﻹﺑﻞ ﻟﮫ ﺗﺄﺛﯿﺮ ﻋﻠﻰ ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦ) (hIRﻛﻤﻀﺎد ﻟﻠﺴﻜﺮي ،ﻟﻜﻦ ھﺬا
اﻟﺘﺄﺛﯿﺮ ﻟﺤﻠﯿﺐ اﻹﺑﻞ ﻏﯿﺮ واﺿﺢ ﺣﺘﻰ اﻵن ﻋﻠﻰ ﻣﺴﺘﻮى اﻟﺒﯿﻮﻟﻮﺟﯿﺎ اﻟﺠﺰﯾﺌﯿﺔ )اﻟﻤﺴﺎرات اﻟﻤﻮﺟﻮدة داﺧﻞ
اﻟﺨﻠﯿﺔ( .ﺣﺪﯾﺜﺎ ً ،وﺟﺪت دراﺳﺔ أن ﺑﺮوﺗﯿﻨﺎت ﺣﻠﯿﺐ اﻹﺑﻞ ﻣﺜﻞ ﺑﺮوﺗﯿﻦ ﻣﺼﻞ اﻟﻠﺒﻦ) (CWPsوأﺟﺰاءه
)(CWPs hydrolysatesﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ﺑﺮوﺗﯿﻦ ﻻ ﻛﺘﻮﻓﺮﯾﻦ ) ،(CMLFﻟﮭﺎ ﺗﺄﺛﯿﺮ إﯾﺠﺎﺑﻲ ﻋﻠﻰ زﯾﺎدة
ﻧﺸﺎط ﻣﺴﺘﻘﺒﻼت اﻷﻧﺴﻮﻟﯿﻦ ﻓﻲ ﺧﻼﯾﺎ اﻹﻧﺴﺎن .ﺧﻼل دراﺳﺘﻨﺎ ھﺬه ،ﺗﻤﺖ ﺗﻨﻘﯿﺔ اﻟﺒﺮوﺗﯿﻨﺎت اﻟﺘﻲ ذُﻛﺮت ﺳﺎﺑﻘﺎ ً
ﻣﻦ ﺣﻠﯿﺐ اﻹﺑﻞ وﻣﻌﺎﯾﻨﺔ ﻛﯿﻔﯿﺔ ﺗﺄﺛﯿﺮھﺎ ﻋﻠﻰ وظﯿﻔﺔ وﻧﺸﺎط ﻣﺴﺘﻘﺒﻼت اﻹﻧﺴﻮﻟﯿﻦ ،ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ دراﺳﺔ
ﺗﺄﺛﯿﺮھﺎ ﻋﻠﻰ اﻟﻤﺴﺘﻮى اﻟﺠﺰﯾﺌﻲ ﻟﻠﺨﻼﯾﺎ ﺑﺎﺳﺘﺨﺪام ﻧﻮﻋﯿﻦ ﻣﻦ اﻟﺨﻼﯾﺎ )ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﻜﺒﺪ  HepG2و
ﺧﻼﯾﺎ اﻟﻜﻠﻰ اﻟﺠﻨﯿﻨﯿﺔ ) .(HEK293ﻹﺗﻤﺎم ھﺬه اﻟﺘﺠﺎرب ،اﺳﺘَﺨﺪﻣﺖ ﺗﻘﻨﯿﺔ  BRETﻟﺘﻘﯿﯿﻢ وظﯿﻔﺔ ﻣﺴﺘﻘﺒﻼت
اﻷﻧﺴﻮﻟﯿﻦ ﻓﻲ اﻟﺨﻼﯾﺎ اﻟﺤﯿّﺔ،إﺿﺎﻓﺔ إﻟﻰ ﺗﻘﯿﯿﻢ ﺗﻔﻌﯿﻞ ﻧﺸﺎط ﻛﻞ ﻣﻦ ﺑﺮوﺗﯿﻦ  Aktو  ERK1/2ﻋﻦ طﺮﯾﻖ
ﻣﺎ ﯾﺴﻤﻰ ﺑﺎﻟﻔَﺴﻔَﺘﺔ )أي ارﺗﺒﺎطﮭﻢ ﺑﻔﻮﺳﻔﺎت( .أﯾﻀﺎ ً ﻗﯿﺎس ﻣﺴﺘﻮى أﺧﺬ واﺳﺘﯿﻌﺎب اﻟﺨﻼﯾﺎ ﻟﻠﺴﻜﺮ ﻟﻠﺤﺼﻮل
ﻋﻠﻰ ﺻﻮرة أوﺿﺢ ﻟﺮﺑﻄﮭﺎ ﻣﻊ ﺗﺄﺛﯿﺮ ﺣﻠﯿﺐ اﻹﺑﻞ ﻋﻠﻰ ﺧﻔﺾ اﻟﺴﻜﺮي .دراﺳﺘﻨﺎ أﺛﺒﺘﺖ أن ﺑﺮوﺗﯿﻨﺎت ﻣﺼﻞ
اﻟﻠﺒﻦ وﻻﻛﺘﻮﻓﺮﯾﻦ ﺑﺤﻠﯿﺐ اﻹﺑﻞ ،ﺗﻘﻮم ﻋﻠﻰ ﺗﻔﻌﯿﻞ ﻧﺸﺎط ﻛﻞ ﻣﻦ  Aktو  ERK1/2ﻋﻦ طﺮﯾﻖ ﻣﺎ ﯾﺴﻤﻰ
ﺑﺎﻟﻔﺴﻔﺘﺔ .ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ھﺬه اﻟﻨﺘﺎﺋﺞ ،ﺑﺎﺳﺘﺨﺪام ﺗﻘﻨﯿﺔ  BRETﺗﻢ ﺗﺄﻛﯿﺪ اﻟﺘﺄﺛﯿﺮ اﻹﯾﺠﺎﺑﻲ ﻟﺒﺮوﺗﯿﻨﺎت ﻣﺼﻞ
اﻟﻠﺒﻦ وﻻﻛﺘﻮﻓﺮﯾﻦ ﻋﻠﻰ وظﯿﻔﺔ وﻧﺸﺎط ﻣﺴﺘﻘﺒﻼت اﻷﻧﺴﻮﻟﯿﻦ اﻋﺘﻤﺎدا ً ﻋﻠﻰ ﺗﺮاﻛﯿﺰ ﻣﻌﯿﻨﺔ .ﻋﻼوة ً ﻋﻠﻰ
ذﻟﻚ،ﻋﻨﺪ إﺿﺎﻓﺔ ﺑﺮوﺗﯿﻨﺎت ﻣﺼﻞ اﻟﻠﺒﻦ وأﺟﺰاءھﺎ ﺑﺬات اﻟﻮﻗﺖ ﻣﻊ ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦ ،أظﮭﺮت زﯾﺎدة أﻛﺒﺮ
ﻟﻨﺸﺎط ﻣﺴﺘﻘﺒﻼت ھﺮﻣﻮن اﻹﻧﺴﻮﻟﯿﻦ .وﺗﻢ اﻟﺘﺄﻛﺪ ﻣﻦ ﺻﺤﺔ ھﺬه اﻟﻨﺘﺎﺋﺞ ﺑﺎﺳﺘﺨﺪام ﻣﻀﺎدات )(antagonists
ﻟﻺﻧﺴﻮﻟﯿﻦ .ﺣﯿﺚ أن ھﺬه اﻟﻤﻀﺎدات ) (S961ﺗﺘﻨﺎﻧﻔﺲ ﻣﻊ اﻹﻧﺴﻮﻟﯿﻦ ﻟﻺرﺗﺒﺎط ﺑﺪﻻّ ﻣﻨﮭﺎ ﺑﻤﺴﺘﻘﺒﻼت
اﻹﻧﺴﻮﻟﯿﻦ.أﺧﯿﺮا ً ،اﻟﻨﺘﺎﺋﺞ اﻟﺘﻲ ﺣﺼﻠﻨﺎ ﻋﻠﯿﮭﺎ ﺑﺎﺳﺘﺨﺪام  BRETو ﻋﻤﻠﯿﺎت اﻟﻔﺴﻔﺘﺔ ،ﺗﻮاﻓﻘﺖ ﺑﺸﻜﻞ راﺋﻊ ﻣﻊ
ﻧﺘﺎﺋﺞ ﻣﺴﺘﻮى أﺧﺬ واﺳﺘﯿﻌﺎب ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﻜﺒﺪ ﻟﻠﺴﻜﺮ .وأﺛﺒﺘﺖ ﻛﯿﻔﯿﺔ ﺗﺄﺛﯿﺮ ﺣﻠﯿﺐ اﻹﺑﻞ ﻋﻠﻰ وظﯿﻔﺔ
ﻣﺴﺘﻘﺒﻼت اﻹﻧﺴﻮﻟﯿﻦ ،واﻟﺬي ﺑﺪروه ﯾﻤﺜّﻞ أول دراﺳﺔ ﺗﻘﻮم ﺑﺈظﮭﺎر ﺗﺄﺛﯿﺮ ﺣﻠﯿﺐ اﻹﺑﻞ ﻋﻠﻰ ﺧﻔﺾ اﻟﺴﻜﺮ
ﻋﻠﻰ اﻟﻤﺴﺘﻮى اﻟﺠﺰﯾﺌﻲ ﻟﻠﻤﺴﺎرات اﻟﺪاﺧﻠﯿﺔ ﻟﻠﺨﻼﯾﺎ.
ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :ﺣﻠﯿﺐ اﻹﺑﻞ ،داء اﻟﺴﻜﺮي ،ﻣﺴﺘﻘﺒﻼت ھﺮﻣﻮن اﻷﻧﺴﻮﻟﯿﻦ ،اﻷﻧﺴﻮﻟﯿﻦ ،ﺟﻠﻮﻛﻮز.
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Chapter 1: Introduction
1.1 Diabetes and the insulin receptor
1.1.1 Definition and characteristics
Diabetes mellitus (DM) is now recognized as the world’s fastest growing
chronic condition, and the most common one. With urbanization, easy access to fast
food, inactive lifestyles and increasing incidence of obesity, its global prevalence has
increased to 8.8% with 425 million adults (20-79 years) living with diabetes in 2017
(Figure 1) [1]. The International Diabetes Federation predicts that, following the
current trend in increase, these numbers are expected to rise to 629 million in 2045. In
the United Arab Emirates, the prevalence was recorded to be 17.3% in 2017, i.e.,
almost twice the current global average, and is expected to hike up to 23.4% in 2045
(Figure 2) [1, 2].

Figure 1: Estimated age-adjusted prevalence of diabetes in adults in the world in
2017 (20-79 years) [1].

2

Figure 2: Prevalence of diabetes and impaired glucose tolerance (IGT) in the UAE in
2017 compared to the expected increase in 2045 [2].
Diabetes is mainly characterized by high blood glucose levels defined as >126
mg/dl while fasting and >200 mg/dl 2 hours after ingestion of glucose (by the
American Diabetes Association) [3]. Currently, diabetes has been classified into two
major types (Figure 3). Type 1 DM (T1DM) is defined as an autoimmune disorder
where the body attacks its own insulin producing pancreatic β-cells. Type 2 DM
(T2DM) develops in the later stages of life and is characterized by insulin resistance
and deficiency in insulin secretion due to progressive loss of β-cell function [3]. It is
still unclear which event precedes the other, but a popular opinion is that insulin
resistance develops early in the course of type 2 DM. Pancreatic β-cells then begin and
continue to overproduce insulin to compensate for this resistance. As the disease
progresses over the years, there is a gradual impairment of these β-cells and
consequently, in insulin production, hence, reducing the body’s ability to compensate
and resulting in hyperglycemia and diabetes [4, 5]. It is difficult to pinpoint an exact
primary cause of DM, but adiposity, inflammation and genetic predisposition are a few
key factors that contribute to the development of insulin resistance. The third common
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type, gestational diabetes, usually develops in the initial stages of pregnancy and
normally rectifies itself by delivery [3].

Figure 3: Differences in pancreatic insulin secretion and insulin receptor activity in
healthy individuals versus T1DM and T2DM patients [6].
Hyperglycemia does not have any immediate harmful effects, but over the
years, persistent high blood sugar levels can have deteriorating effects on blood vessels
and organs like kidneys, eyes and heart. The pathophysiology of diabetes is complex
and involves many biological processes. For majority of diabetics, in addition to
insulin therapy, more than one drug is often used to combat different aspects of the
disease and maintain glucose homeostasis. Apart from maintaining a healthy lifestyle
and diet, effective clinical management of diabetes involves the careful selection of
drugs that complement each other and minimize the risk of negative side effects such
as hypoglycemia. Consistent control of blood glucose levels in patients with insulin
dependent diabetes effectively delays and slows down the development of
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complications like diabetic retinopathy and nephropathy [7]. As research uncovers
more and more about the pathogenic complexity of diabetes, there is an ensuing
increase in the search for better and easier treatment options.
1.1.2 Insulin receptor and its signaling pathways
Insulin is a 51 amino acid long anabolic hormone secreted by β-cells in the
Islets of Langerhans of our pancreas in response to rises in blood sugar levels.
Discovered almost a hundred years ago, it is most famously known for being the key
player in glucose and lipid homeostasis in the body [8]. In broad terms, insulin
promotes the uptake and storage of fuel as glycogen and fats, and prevents breakdown
of stored fuel [9]. Insulin is initially synthesized in the pancreas as a 110 amino acid
polypeptide called pre-proinsulin. Almost immediately it is transferred to the
endoplasmic reticulum where it undergoes cleavage and loses its signal peptide to form
proinsulin [10]. Finally, a middle fragment of proinsulin is removed by proteolytic
cleavage leaving us with the two chains of mature insulin (A and B) held together by
disulphide bridges [11]. Insulin achieves its effects through its human receptor (hIR)
present in the plasma membranes of its target cells – the most prominent ones being
hepatocytes, adipocytes, skeletal muscle cells, pancreatic β-cells and neurons [12].
The hIR belongs to the tyrosine kinase family of receptors (RTK). Together
along with insulin-like growth factor receptors (IGFR) and the orphan receptor, they
form the IR subfamily. All receptors in the IR family are synthesized as one protomer
protein which then is proteolytically cleaved to form α and β polypeptide chains. For
the hIR, these chains are finally assembled into disulfide linked homodimers where
each monomer is the αβ heterodimer. This αβ monomer is coded for by a gene with 22
exons. After translation, the pre-mRNA undergoes alternative splicing of exon 11 to
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create two variants of the hIR without and with the exon; IR-A and IR-B respectively.
The α subunit of hIR is entirely extracellular and contains the ligand binding domains
of the receptor. Meanwhile, the β subunit spans the plasma membrane once and then
constitutes the cytoplasmic subunit, possessing its characteristic tyrosine kinase
domain [13].

Figure 4: Schematic representation of the Akt/PI3K and MAPK/ERK pathways
initiated by the insulin induced activation of the hIR. Adapted from [4].
When insulin binds to α subunit, it causes a conformational change in the
receptor bringing the two β subunits together in the plasma membrane. This
consequently allows autophosphorylation of hIR at specific tyrosine residues and
activation of its kinase activity. We know now that the downstream signaling pathways
initiated by insulin binding to the hIR cannot be explained as a single line of events
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one preceding the other, but as a complex and integrated network involving branching
out at several steps and crosstalk between pathways arising from hIR as well as other
receptors. The major two pathways by which the hIR controls its metabolic and
mitogenic effects are Akt/protein kinase B (PKB) pathway and ERK/mitogenactivated protein kinase (MAPK) pathway respectively (Figure 4). These pathways
begin with the recruitment and subsequent activation of the scaffolding proteins,
insulin receptor substrate protein (IRS) and Shc to the hIR via their phosphotyrosine
binding (PTB) domains. In the PKB/Akt pathway, phosphoinositide 3-kinase (PI3K)
bind to IRS, via its SH2 domain [14, 15]. Here, the IRSs do not contain any intrinsic
kinase activity, but act as scaffolds to bring PI3K close and allow their phosphorylation
by hIR. PI3K then activates protein dependent kinase 1 (PDK1) which in turn activates
PKB/Akt. Activation of PKB is responsible for the mediation of major metabolic
effects of insulin such as increase in glucose uptake by translocation of glucose
transporter 4 (GLUT4) from cytoplasmic vesicles to the plasma membrane, and also
activation of glycogenesis [9, 16]. Glucose transport proteins like GLUT4 help in
uptake of extracellular glucose from the blood to inside the cell via an ATP
independent mechanism [15].
Another signal transduction protein, Grb2 interacts with IRS to initiate the
ERK/MAPK pathway. Grb2 then phosphorylates Ras which in turn initiates the
Ras/Raf/MEK cascade leading to the activation of MAP kinases such as p38, c-Jun Nterminal kinase (JNK) and ERK1/2 [14]. The MAPK/ERK pathway is the mitogenic
arm of IR signaling and is responsible for gene expression related to cell growth,
proliferation and differentiation. Similar to IRS, Shc is another scaffolding protein
that binds to hIR and is seen to initiate the ERK/MAPK pathway in an IRS independent
mechanism [14].
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1.1.3 IR, insulin resistance and diabetes
Insulin resistance is the body’s inability to effectively use physiologically
normal concentrations of insulin to maintain glucose homeostasis. Although insulin is
a pleiotropic hormone, ‘insulin resistance’ usually refers to its actions on blood glucose
levels. Everybody with insulin resistance is not diabetic and some can maintain
glucose homeostasis by compensatory increase in insulin secretion, while most
patients with both types of diabetes exhibit some level of insulin resistance [17, 18].
Moreover in T2DM,together along with obesity, is one of the major risk factors and is
seen in pre-diabetic patients more than 10 years before the onset of the disease [18,
19].
The contributing factors for diabetes involve complex interplay between
environmental and genetic parts. Obesity, inactive lifestyles, stress and excessive
nutrition are some of the most common environmental triggers. The genetic
contribution to the development of diabetes is made clear by its heritability. First
degree relatives of diabetic patients have a much higher risk of developing the diseases
as compared to the general population [20]. On a genetic basis, diabetes can be
monogenic, i.e. arise as a result of just one defective gene, or polygenic, where effects
of several altered genes (mainly involved in insulin signaling and β-cell growth and
proliferation) add up to create the diabetic phenotype [21].
Genome wide association studies have identified more than 50 genetic loci
associated with T1DM , the most studied of these being mutations in HLA genes [22].
When it comes to T2DM, these studies have exposed at least 75 different genetic loci.
However, the reasons for the effects of these mutations are still unknown [23]. There
are rare monogenic forms of T2DM such as maturity onset diabetes of the young
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(MODY), but majority of them are polygenic involving mutations at multiple genetic
loci [23].
Being the key pathway when it comes to maintenance of glucose homeostasis
by the hIR, defects related to proteins involved in the metabolic PI3K/Akt signaling
cascade obviously play an important role in the pathogenesis of insulin resistance. The
first critical node in this pathway is the hIR itself [15]. More than 60 different
mutations affecting the hIR have been identified, most of them resulting in diseases
involving insulin resistance like the Rabson-Mendelhall syndrome, leprechaunism and
type-A insulin resistance. Some of these variants have been associated with higher risk
of developing T2DM [24]. Multiple in vitro studies on skeletal muscle cells isolated
from diabetic patients reveal faults with IR including markedly reduced
autophosphorylation in response to insulin, lower expression levels and defective
kinase activity [25–28]. The IRS scaffolding proteins fall next in line in the pathway.
Decreased tyrosine phosphorylation of IRS1 and IRS2 has been observed in diabetic
and severely obese patients [25, 28]. It is interesting to note that in mice knockout
studies with disruption of IRS2, the mice exhibited diabetic phenotype with insulin
resistance and impaired beta cell secretion of insulin. However, with the disruption of
IRS1, mice only developed insulin resistance suggesting compensatory increase in
insulin levels by the pancreatic beta cells [5]. Reduction in tyrosine phosphorylation
of PI3K is another factor that contributes to insulin resistance in diabetic and
prediabetic individuals [25, 28, 29]. The next important protein in this signaling
pathway is Akt. It is now known that mutations in the kinase domain of Akt2 are
associated with severe insulin resistance and diabetes [15]. Consequent effects of
defective IRS, PI3K and Akt activation is also seen significant attenuation of GLUT4
translocation and glucose uptake and utilization by insulin sensitive peripheral
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tissues[18, 25, 30]. Another cause of ineffective control of glucose levels in the body
are missense mutations in the insulin hormone gene. It results in the productions of
structurally abnormal insulin leading to problems in its biological activity and receptor
binding abilities [31].
1.1.4 Therapies targeting the hIR
Effective maintenance of glucose homeostasis over the years is the most
effective way to decrease the adverse effects of hyperglycemia on organs such as eyes,
heart and kidneys. Currently the best method of treatment for this is by administering
exogenous or insulin analogs to help cope with insufficiency of biologically active
insulin or impaired activity of the hIR. However, these treatments are not without
negative side effects. Excessive activation of the insulin induced mitogenic
MAPK/ERK pathway can cause weight gain and increased risk of cancer development.
Occasional hyperinsulinemia can lead to hypoglycemic episodes [4, 32]. Additionally,
these high levels of insulin can lead to an unwanted increase in the activation of other
cellular processes like increased androgen production by the ovaries [17]. Recent
research has been focusing on alternative treatments that target the hIR and activate
only its glucose lowering metabolic pathways without the mentioned side effects [32].
A few examples have been discussed below.
Qiang et al. (2014) reported the discovery of 4548-G05, a metabolite of the
fungi Chaetomium gracile, and a non-peptidyl insulin mimetic which specifically
activates the insulin receptor by binding to its extracellular region in the absence of
insulin [33]. 4548-G05 activates both Akt and ERK signaling pathways downstream
of the hIR while also increasing glucose uptake. In mouse models of T1DM and
T2DM, it reduces blood glucose back to normal healthy levels [33]. Another potential
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candidate is the synthetic insulin mimetic peptide S597 which showed high hIR
binding affinity and activation of its kinase activity. It partially phosphorylated the hIR
and exhibited biased agonism by activating the metabolic pathway almost to the level
of insulin with negligible stimulation of the mitogenic pathway. Even high
concentrations of S597 only partially stimulated the MAPK/ERK pathway.
Accordingly, this peptide did not show much effect on cell proliferation [34].
Bhaskar et al. (2012) identified a promising candidate, XMetA – a fully human
monoclonal antibody which is a positive allosteric modulator highly specific to the
hIR [35]. XMetA binds to hIR with an affinity higher than insulin but causes only
partially activation of the metabolic Akt pathway (about 40% of what is activated by
insulin) and does not potentiate the mitogenic MAPK/ERK pathway [35]. It’s
interesting to note that XMetA does not compete with insulin since it binds to
completely different site giving it the advantage of being used in conjunction with
insulin and other current diabetic drugs. Moreover, it takes away the risks associated
with complete inhibition of natural hormonal mechanisms [36]. In vitro experiments
in 3T3 cells confirmed consequent glucose uptake after activation of Akt, while in vivo
experiments in STZ induced diabetic rats , cynomolgus monkeys and rhesus monkeys
showed that XMetA normalized both fasting and non-fasting blood glucose levels,
along with other metabolic indices of diabetes [35, 37–39]. Even in insulin resistant
diet induced obese mice, XMetA improved fasting glucose as well as insulin tolerance
[38]. This character offers XMetA the potential of therapeutic use in patients where
activation of IR by insulin is defective [37]. More excitingly, these positive effects
come without side effects such as hypoglycemia and weight gain [38]. Another studied
monoclonal antibody is IRAB-A, identified by Hinke et al.by phage screening assays
with the IR extracellular domain. Similar to XMetA, in vitro assays using IRAB-A
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identified it as an allosteric agonist with specificity to the insulin receptor. It was also
observed to stabilize ligand binding and also increased sensitivity of the hIR to insulin
coupled with higher glucose uptake. The same group also identified an hIR antagonist,
IRAB-B. IRAB-B treated mice showed rapid development of hyperglycemia, sever
insulin resistance, decreased phosphorylation of Akt, IRS1, glucose uptake as well as
body weight [40]. As compared to the current methods, IRAB-B shows the potential
to be a more cost effective and faster way to induce insulin resistance in mammalian
models to study the pathophysiology of impaired insulin receptors [40].
Along with XMetA, Bhaskar et al.(2014,2014) also identified two other
antibodies that interact with the hIR – XmetD and XMetS [41, 42]. XMetD is a highly
specific allosteric insulin receptor antagonist. In vitro experiments showed that XMetD
markedly decreased insulin affinity, IR autophosphorylation as well as downstream
events including Akt phosphorylation and glucose transport. What’s more is that it did
not show any effects in the absence of insulin [42]. Most importantly, in mice induced
with hyperinsulinemic hypoglycemia XMetD treatment returned blood glucose to
normal levels [42]. XMetS, on the other hand, enhanced the sensitivity of hIR to
insulin by stabilizing the insulin – receptor conformation by decreasing their
dissociation rate. Similar to XMetA, XMetS showed biased activity, enhancing the
activation of only the metabolic or Akt pathway without much effect on the ERK
pathway [41].
The modifications that these treatments cause to hIR signaling patterns are
hypothesized to be the result of structural modulations to the IR brought about by
binding to non-orthosteric sites [43]. While the research involving these treatments are
still in the preliminary stages and not without the possibility of unidentified long term
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effects, studying the structural mechanisms could bring us closer to understanding the
working of the IR and also to the development of new therapeutics for diabetes [32].
1.2 Camel Milk
For centuries, in communities that inhabit the drier areas of Asia and Africa,
CM has been more than just the traditional source of nutrition. Throughout history, the
therapeutic nature of CM has been reported against multiple diseases like tuberculosis,
asthma, jaundice and leishmania [44, 45]. Rightfully called ‘the white gold of the
desert’, CM has come into the research spotlight in the recent years, with scientists in
different parts of the world uncovering its various medicinal properties including
antimicrobial, anti-carcinogenic, anti-hypertensive, anti-oxidant and anti-diabetic
properties [46].
1.2.1 Chemical composition of CM
In general, CM is composed of about roughly 80-90% water, 2-4% fat, 3-4%
protein, 4-5% lactose, along with vitamins and minerals [47]. However, the specific
percentages of each of the constituents vary based on influence by factors such as
lactation stage, age of the camel, geographic and seasonal conditions [48]. Compared
to bovine milk, CM has lower cholesterol and fat content. Moreover, this fat is mainly
polyunsaturated fatty acids. Its fat globules are also the smallest in size when compared
to cow, buffalo and goat milk. The smaller size implies a larger surface to volume ratio
contributing to its easier digestibility [49, 50]. Milk proteins are broadly classified into
caseins and whey proteins. In CM, caseins constitute about 75% of all protein while
whey proteins make up the other 25%. The major protein fractions in camel whey are
immunoglobulins, camel serum albumin, α-lactalbumin, lactophorin A, and
lactoferrin. In contrast to bovine milk where β-lactoglobulin is the most abundant whey
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protein, α-lactalbumin is the most abundant camel whey protein. β-lactoglobulin is one
of primary culprits when it comes to milk allergies and lactose intolerance. Moreover,
camel whey actually lacks β-lactoglobulins, making it safe even for such patients [51,
52]. Camel whey also contains high concentrations of antimicrobial proteins and
immunoprotective bioactive compounds like lactoferrins, immunoglobulins IgG and
IgM and lysozyme [53]. To add to this exceptional list of benefits, CM is also rich in
vitamin C, A, D and riboflavin. Additionally, its mineral profile is similar to that of
human milk with high concentrations of iron, copper, zinc and potassium [48].
1.2.2 Antidiabetic properties of CM
Many previous studies using animal models and humans have shown beneficial
effects of CM in diabetes by reducing blood sugar, improving pancreatic β-cell
function, decreasing insulin resistance and improving lipid profiles [54–60]. It has
been suggested as an adjunct to insulin therapy because it can effectively reduce the
amount of insulin required by diabetics. One study contended a significant reduction
(46.15%) in insulin doses required by Type 1 diabetic patients who consumed raw CM
for 2 years (Figure 5) [61]. In another study conducted in the camel breeding and
rearing Raika tribe of India, the incidence risk of diabetes was very low in communities
that regularly consumed camel versus those that did not [62]. It is also known to
alleviate other pathophysiological effects associated with diabetes such as obesity,
inflammation, wound healing, diabetic nephropathy and oxidative damage [63–66].
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Figure 5: Graphical representation of the reduction in mean doses of insulin required
in T1DM patients consuming CM over the course of 2 years [61].
While we cannot pinpoint an exact reason for these antidiabetic effects, recent
studies have identified a few contributing factors. CM contains approximately 3 times
more insulin like peptide (52 micro unit/L) as compared to bovine milk. Interestingly,
camel and bovine milk insulin is only one amino acid different from each other, but
no hypoglycemic activity has been reported yet for bovine milk. Hence, it is more
plausible that it is not the insulin itself but its cooperation with the other characteristics
of CM that helps with glucose homeostasis [67]. An important factor here is that CM
does not coagulate in our stomach’s acidic environment, probably making it easier for
this insulin-like peptide to be readily absorbed and passed into the blood stream [61].
Moreover, certain CM proteins have amino acid sequences that are rich in half cystine
residues, much like the insulin family of proteins. Another explanation could be the
unique property of these peptides in CM to be encapsulated by lipid nanoparticles,
effectively protecting them from proteolysis in the stomach. The fact that CM is rich
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in zinc could be another contributing factor, since zinc enhances and stabilizes insulinIR interaction [68, 69].
The antidiabetic nature of CM is the most famous amongst all its medicinal
values and has been continuously verified by in-vivo studies on both animal models
and diabetic patients [54, 58, 61, 68]. However, when it comes to the cellular and
molecular mechanisms behind this effect, we’ve only scratched the surface. Our
research explores the effects of CWPs and its fractions on one of the primary targets
in diabetes: the hIR. We have also looked into the subsequent activation of its signaling
pathways and glucose uptake into cells.
1.2.3 Molecular and cellular mechanisms of the antidiabetic effects of CM
While many in vivo studies have proven the hypoglycemic effects of CM, we
are still in the early stages of defining the responsible molecular mechanisms. These
anti-diabetic effects cannot be attributed to one CM component. It is rather the result
of harmonious action of multiple components on different targets in the body. The
studies discussed below have proven that these targets can not only be those directly
associated with diabetes such as the IR, pancreatic β-cells and glucose transporters,
but also factors that contribute to the pathogenesis of diabetes, such as obesity,
inflammation and oxidative stress (Figure 6) [55, 66, 70–76].
One study discovered potent dipeptidyl peptidase-4 (DPP4) inhibitory peptides
in tryptic hydrolysates of CM [70]. DPP4 is a protease that inactivates incretins, i.e.,
glucagon like peptide-1(GLP-1) and gastric inhibitory polypeptide (GIP). Incretins are
gut hormones released when food containing sugars and lipids travels into the small
intestine. They signal the pancreas to produce insulin in accordance to the glucose
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ingested and inhibit the release of glucagon. This is known as the incretin effect.
Inhibiting DPP4 slows down incretin degradation allowing their effects to last longer,
consequently increasing insulin secretion [70].
Additionally, treatment with CM reduced diabetic oxidative stress by
significantly decreasing free radicals and production of pro-inflammatory cytokines
like interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) [71]. Diabetes
(both T1DM and T2DM) is well known to be a chronic inflammatory disease where
high levels of inflammatory cytokines and continued oxidative stress contribute
largely to the pathogenesis and also development of complications in diabetes [72, 73].
Conversely, CM increased their anti-inflammatory counterparts IL-2 and IL-4 in
diabetic mice. This could be due to the direct action of CM proteins, like lactoferrin
and β-casein, which exhibit anti-inflammatory and anti-oxidant properties. However,
it is also possible that the lowered glycemic levels indirectly diminishes the existing
inflammation [60, 75]. Additionally, peptic hydrolysis of colostral CM produces
bioactive peptides with increased antioxidative properties as compared to the milk
before hydrolysis [74]. ATF-3 expression and phosphorylated protein kinase B (Akt)
are two other targets studied. High ATF-3 levels are indicative of increased proapoptotic genes, while decreased Akt phosphorylation influences the development of
diabetes. Treatment with CWPs brings both these factors back to normal levels in
diabetic mice [71]. It is possible that DPP4 inhibition along with anti-inflammatory,
anti-apoptotic and anti-oxidant properties is the basis for increased pancreatic insulin
secretion observed in diabetic patients and animals [55, 75, 76]. After all, inflammation
and apoptosis of insulin-secreting pancreatic β-cells certainly is a prime event in both
types of diabetes.
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A recent in vitro study by A.O. Abdulrahman et al. suggests that CM directly
interacts with hIR [77]. It weakly activated hIR but significantly increased its
sensitivity to insulin, suggesting an allosteric mode of action. The study also narrowed
down the putative agent to a peptide/protein component in the milk whey fraction [77].
In the light of this study, our main objective for this thesis was to test the effect of
CWPs and its fractions on hIR function, and subsequent glucose uptake, in vitro. Direct
interaction of CM with the hIR opens up the possibilities of positive allosteric
modulation of other associated receptors such as those specific for GLP1 , GIP and
the IGFR, or even negative allosteric modulation of the glucagon receptor [78].

Figure 6: Probable molecular targets of camel milk components in the cell that could
help explain its antidiabetic properties [78].
Among the constituents of CM, lactoferrin (LF) stands out as a potential player
when it comes to its antidiabetic effects. Associations between LF and glucose
homeostasis were initially made by Moreno Navarette et al. when they discovered that
levels of plasma LF are significantly reduced in T2 diabetics with increased insulin
resistance [79]. They highlighted that LF effects the insulin signaling pathway by
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potentiating IR-mediated Akt phosphorylation and increasing GLUT4 and IR
expression on adipocytes [79, 80]. Moreover, literature shows that increased plasma
LF is associated with decreased expression of inflammatory markers and overall
adiposity [81, 82]. Both of which are significant risk factors in the pathogenesis of
diabetes. Plasma LF levels are also inversely related to abdominal as well as overall
adiposity while consistent oral consumption decreased abdominal visceral fat in men
[81, 83, 84]. Lastly, it even inhibits the production of several proinflammatory
cytokines including TNF-α, IL6 and IL 1β [85].
Another possible candidate is adiponectin, a metabolic adipokine secreted by
the white adipose tissue and present in high concentrations in CM. Higher circulating
adiponectin levels have been correlated with increased insulin sensitivity while
reduced levels of plasma adiponectin have been commonly observed along with
insulin resistance, T2DM, obesity and cardiovascular diseases [86, 87].
Lastly, as mentioned in some studies above, CM peptides add one more
category to its potential antidiabetic components. Gastrointestinal digestion of food
proteins releases and activates encrypted peptides within it. These peptides have, more
often than not, higher biological activity when compared to the parent protein. In
general, milk is one of the major sources of food derived bioactive peptides. The
peptides present in CM hydrolysates, generated by lysis by digestive enzymes, show
significant DPP4 inhibition, wound healing and anti-obesity properties in the context
of diabetes [57, 70, 88].
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Chapter 2: Hypothesis, Objectives and Approach
We hypothesize that the hypoglycemic properties of CM observed in vivo may
involve the action of CWPs, its hydrolysates and LF on the intracellular signaling
pathways mediated by insulin.
In order to better understand how CWP affects the hIR at the molecular level,
our objectives were to study these effects on different aspects of IR function in vitro
as given below:
1. Pharmocological effect of CWPs, its hydrolysates and LF on the
intracellular signaling pathways mediated by hIR by studying the
phosphorylation status of intracellular kinases ERK1/2 and Akt as well as
IR itself.
2. Physical association of IR with the substrate protein IRS1 on treatment with
CWPs, its hydrolysates and LF.
3. Effect of CWPs, its hydrolysates and LF on the function of glucose uptake
into the cells via translocation of glucose transporters (e.g. GLUT4) from
their cytoplasmic vesicles to the plasma membrane.
Table 1: Objectives and their respective approaches used in this thesis
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Chapter 3: Materials and Methods
3.1 Chemicals, reagents and plasmids
Human insulin and bovine LF was purchased from Sigma Aldrich. The hIR
antagonist peptide, S961, was a gift from Dr. Lauge Schäffer (Novo Nordisk,
Copenhagen, Denmark). Camel LF was generously provided by Dr. Elrashdy M.
Redwan (King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia).The plasmids
coding for Renilla luciferase-fused hIR (hIR-Rluc) and YFP-tagged IRS1 (IRS1-YFP)
used for transient transfections in HEK293 cells were kindly provided by Dr. Rasmus
Jorgensen (Hagedorn Research Institute, Novo Nordisk, Gentofte, Denmark), Dr.
Tarik Issad (Cochin Institute, Paris, France), respectively. Correct expression of the
yellow fluorescent proteins (YFP) tagged proteins was verified visually by using
fluorescence microscopy and by reading light emission at 540 nm using the Tristar 2
plate reader. The same instrument was used to verify expression of hIR-Rluc by
measuring light emissions at 480 nm upon the addition of Rluc substrate.
3.2 Bacterial transformation and plasmid extraction
The hIR-Rluc and IRS1-YFP plasmids were first dissolved in 50 µL nuclease
free water. Transformation was carried out using NEB® 5-alpha competent E. coli cells
(New England BioLabs Inc.) The bacteria and plasmids were mixed together as per
manufacturer’s instructions. Briefly, after gentle mixing, the plasmid-bacteria mixture
was incubated on ice for 10 minutes followed by a heat shock for 42 seconds at 45°C
on the heating block, and then returned to ice for 5 more minutes. Next, 500 µL of
SOC Outgrowth Medium (New England BioLabs Inc.) was added to each tube and
incubated for 1 hour at 37°C in the shaking incubator. This was followed by
centrifugation at 5000 rpm for 5 minutes, after which the supernatant was discarded,
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and the pellet resuspended in 50-100 µL of SOC medium. This mixture was spread
evenly onto agar plates containing the antibiotic ampicillin (Sigma) for colony
selection and incubated at 37°C for 24-36 hours.
One colony from the transformed plates for each plasmid was picked and
dropped into 200 mL of LB media supplemented with ampicillin. The resuspended
colony was grown in liquid culture overnight at 37°C overnight in the shaking
incubator. The transformed bacteria were pelleted from the suspension culture the next
day by centrifugation at 6000 rpm for 15 minutes. The pellets were stored at -20°C
before being used for plasmid extraction.
Plasmids were extracted from the bacterial pellets using the Qiagen® Plasmid
Maxi kit following manufacturer’s protocols. Extracted DNA was finally resuspended
in nuclease-free water and plasmid concentrations were measured using the NanoDrop
2000 (Thermo Scientific). Plasmid integrity was checked using agarose gel
electrophoresis.
3.3 CM collection, fractionation and hydrolysis
Milk of Camelus dromedarius was kindly provided by Ms. Aysha, (PhD
student in the College of Science) fresh every week from her local farm (Al Ain, UAE).
To obtain the whey proteins for cell treatment, whole milk was first skimmed by
centrifugation at 5000 rpm for 30 minutes at 4°C to remove fat. Caseins were then
separated out by acid precipitation by bringing the pH down to 4.6 using 1M HCl
followed by incubation at 37°C for 30 minutes. The sample was then centrifuged again
for 5000 rpm at 30 minutes at 4°C to precipitate caseins. Clear whey proteins were
collected (supernatant) and pH adjusted to 7.4 (physiological pH) prior to cell
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treatment. All CWP hydrolysates were kindly provided by Dr. Sajid Al Maqsood from
the College of Food and Agriculture, UAEU.
3.4 Cell culture and transfection
Both HEK293 and HepG2 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco) supplied with 10% fetal bovine serum and 100 IU/ml
penicillin, and 100 µg/ml streptomycin (Sigma-Aldrich) at 37°C in 5% CO2.
Transient transfections were carried out when HEK293 cells were
approximately 70% confluent in T75 flasks using Lipofectamine 2000 (Invitrogen) as
per manufacturer’s instructions. Briefly for each flask, plasmids and lipofectamine
were separately mixed with 1mL Opti-MEM (Gibco) each and incubated for 5 minutes
at room temperature. The two mixes were then combined and incubated for another 20
minutes before it was added to the cells in T75 flasks along with DMEM. For BRET
experiments, each flask was transfected with 7.5 µg hIR-Rluc2.5 µg IRS1-YFP, while
for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
western blotting, each flask was transfected with 5 µg of hIR-Rluc.
Twenty four hours after transfection, cells were harvested using TrypsinEDTA (Gibco) and counted with the improved Neubauer chamber. Cells were then
seeded into 96-well plates at a density of 105 cells per well for BRET, or into 6-well
plates at a density of 106 cells per well for western blotting experiments. All
experiments were carried out a total of 48 hours after transfection.
HepG2 cells endogenously expressing hIR were seeded into 6-well plates at a
density of 106 cells/well 48 hours prior to the experiment.
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3.5 Cell treatment and lysis
HEK293 cells and HepG2 cells transiently and endogenously expressing hIR,
respectively, were starved in serum-free DMEM overnight in their 6-well plates. Two
protocols were followed for the treatment: 1) Cells were treated or not with insulin,
camel and bovine whey proteins, hydrolysates of CWPs and LF (bovine and camel),
for 5 minutes to observe ERK1/2 and hIR phosphorylation and 10 minutes for Akt
phosphorylation, at 37°C. The timings for cell treatment were chosen based on the
kinetics for these two pathways when activated by insulin [77]. 10 minutes was the
optimum time for Akt accumulation in the cells after treatment with insulin, while the
peak for ERK1/2 accumulation was at 5 minutes [77]. The same method was also used
to study the effects of co-treatment of the mentioned treatments with insulin. 2) Cells
were pre-treated with whole CWPs or its hydrolysates for 60 minutes before the
addition or not (control) of insulin. In experiments involving the hIR-selective
antagonist (S961), 1 µM of the antagonist was added along with the initial treatments.
After treatment, the cells were washed in ice cold PBS followed by
homogenization, for 90 min at 4°C, with 200 µL/well of ice-cold RIPA lysis buffer
(Merck Millipore) supplemented with phenylmethylsulfonyl fluoride (PMSF) (Roche)
and protease inhibitors (Sigma-Aldrich). Cell lysates that were then scraped and
collected were centrifuged for 15 min at 15000 g (4°C) to remove cell debris. The
supernatants were stored at -20°C until further use.
3.6 Protein quantification by BCA assay
Protein concentrations of the lysates were determined by the BCA assay using
the BCA Protein Assay Kit (Pierce, Thermo Scientific).
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3.7 SDS-PAGE and Western blotting
20 µg of protein from each cell lysates sample was mixed with Laemmli buffer
(Bio-rad) and heated for 5 minutes at 95°C. The samples were then separated by SDSPAGE (225 V for 75 minutes) and transferred to polyvinylidene fluoride (PVDF) (BioRad) membranes by conventional wet-transfer technique (100V for 90 minutes).
Transfer was confirmed by staining with Ponceau (Sigma-Aldrich). The membranes
were then blocked in 5% skimmed milk prepared in PBS (Gibco) containing 0.1%
Tween 20 (Bio-Rad) (PBST) for 1 hour before moving on to immunoblotting. The
membranes were incubated overnight in primary antibodies against Akt, pAkt,
ERK1/2, pERK1/2, IR-β, and pIR-β (Table 2). Anti- rabbit IgG or anti- mouse IgG
conjugated to horseradish peroxidase (HRP) were used as secondary antibodies as per
the source of the primary antibodies. Membranes were treated with secondary
antibodies for 45 minutes before treatment with the chemiluminescent substrate for
detection (Pierce ECL and SuperSignal West Femto, Thermo Scientific). HRP activity
was detected by chemiluminescence using the LI-COR C-digit Blot Scanner (LI-COR
Biosciences.). The whole protocol in also described in Figure 7. All antibodies were
purchased from Cell Signaling Technology, except the anti-pIR (Tyr1334) (Thermo
Fischer).
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Table 2: List of antibodies used and their working dilutions
Antibody

Catalog no.

Dilution used

Akt

9272

1:1000

pAkt (Ser473)

9271

1:800

ERK1/2

4695

1:1000

pERK1/2
(Thr202/Tyr204)

9106

1:2000

IR-β

3020

1:1000

pIR-β (Tyr1345)

3026

1:1000

pIR (Tyr 1334)

44-809G

1:1000

Anti-mouse IgG –HRP

7076

1:3000

Anti-rabbit IgG –HRP

7074

1:3000
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Figure 7: Schematic representation of cell treatment and western blotting.
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Figure 8: Schematic representation of cell treatment for BRET assays.
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3.8 BRET assays
The BRET assay is a technique that can be used to protein-protein interactions
in live cells and in real-time (Figure 8). It operates on the principle of resonance energy
transfer from a bioluminescent donor to fluorescent acceptor based on their proximity.
When the emission spectrum of the donor overlaps with the excitation spectrum of the
acceptor, transfer of energy occurs from the former to the latter. Thus, when the two
proteins are in close proximity (<10 nm), we are able to observe an increase in the
BRET signal (Figure 9). Transfected HEK293 cells co-expressing hIR-Rluc (BRETdonor) and IRS1-YFP (BRET–acceptor) proteins were starved overnight in serum-free
DMEM. Cells were treated with 50 µL/well of respective treatments or PBS (control)
and incubated at 37°C for 60 minutes. When required, S961 was added along with the
treatments at this stage. This was followed by removal of treatment and addition of 40
µL of 2.5 µM coelenterazine h (Promega) prepared in PBS. BRET measurements of
emitted light were immediately carried out using the Tristar 2 multilabel plate reader
(Berthold, Germany) at 480 n and 540 nm.
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Figure 9 : Principle of the BRET assay (adapted from [89]).

3.9 Glucose uptake assay
Glucose uptake into non-transfected HepG2 cells was measured using the
Glucose Uptake-Glo Assay (Promega). Briefly, HepG2 cells that were seeded into 96
well plates at a density of 105 cells/well were washed with PBS and starved in glucose
and serum free medium on the day before the experiment. The experiment was started
by removing the media and adding respective treatments to the wells followed by
incubation for 60 minutes at 37°C. The stimulants were then removed and 25 µL of
freshly prepared 1mM 2-deoxyglucose was added to each well. After 10-15 minutes
at room temperature the reaction was stopped, and cells lysed using provided buffers.
50 µL/well of freshly prepared 2-deoxyglucose-6-phosphate detection reagent
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containing Ultra-Glo™ Recombinant Luciferase was added before incubating the plate
for 15-60 minutes at room temperature. The luciferase activity was measured at 15minute intervals using the Glo-Max® Discover Microplate reader.
3.10 Data and statistical analysis
All BRET, western blotting and glucose uptake experiments were carried out
in triplicates. Bands visualized after western blotting were quantified by taking the
ratio of phosphorylated protein over the respective total protein to compare the rates
of phosphorylation among samples. Quantification of bands and graph generation were
carried out using Image Studio software, Version 5.2.BRET ratios were calculated as
light emissions at 540 nm over 480 nm. From this, the ligand induced BRET was
obtained by subtracting the control (only PBS treated cells) values. Next, all the values
were normalized by taking the insulin induced positive control as 100%. Graphs were
plotted using GraphPad Prism software. Statistical analyses were performed with twoway ANOVA and Tukey's multiple comparisons test to determine statistically
significance between the different conditions. ****p-value < 0.0001, ***p-value <
0.001, ** p-value < 0.01, * p-value < 0.05, and ns p-value > 0.05.
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Chapter 4: Results
4.1 Successful CM whey proteins (CWPs) fractionation and hydrolysis
After removing the fat and casein fractions from fresh CM, we ran them on an
SDS-PAGE gel to confirm the presence of required fractions as well the integrity of
whey proteins. Coomassie staining of the gel revealed clear single bands at around 80
kDa in the lanes for camel and bovine LF signifying the presence of unadultered and
intact LF. Camel and cow whey proteins showed in intact bands as well (Figure10).

Figure 10: Coomassie blue staining of the gel confirming the presence of CWPs and
LFs in the samples.
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4.2 CWPs activate Akt and ERK1/2 pathways in HEK293 and HepG2 cells
As stated above, CM has been reported to have significant anti-diabetic effects
in many in vivo studies. Therefore, we attempted to link such interesting properties of
CM with more integrated cell responses and molecular pathways using two different
cells models, HepG2 cells endogenously expressing hIR and HEK293 cells transiently
expressing or not hIR. For this, we investigated the functional activity of CWPs on the
two major intracellular signaling pathways, Akt and ERK1/2 phosphorylation, known
to be the key hIR-mediated downstream signaling involved in glucose uptake and
homeostasis. As shown in Figure 11A, insulin (1 µM) used as a positive control
significantly increased Akt and ERK1/2 phosphorylation in both HEK293 and HepG2
cells indicating the activation of hIR and validating the experiment. Interestingly,
CWPs (1 mg/ml) also strongly induced Akt and ERK1/2 phosphorylation in HEK293
and HepG2 cells similarly to insulin action (Figure 11A). The overexpression of hIR
in HEK293 seems to increase both insulin- and CWPs-mediated response compared
to mock HEK293 cells (Figure 11A). These data demonstrate the functional activity
of camel milk proteins on Akt and ERK1/2 signaling pathways that might explain the
hypoglycemic effect of camel milk.
Next, we examined the biological activity of CWPs upon in vitro proteolysis
into heterogeneous peptide fractions. The rationale behind this was to mimic the
obvious gastric proteolysis of CM proteins after its consumption. For this, we
subjected CWPs to enzymatic digestions using the key gastric and pancreatic
proteolytic enzymes, trypsin, chymotrypsin and pepsin and we then tested the effect
of their respective hydrolysates at 1 mg/ml on Akt phosphorylation in HEK293 cells.
As shown in Figure 11D, while trypsin hydrolysate fully lost its activity the
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chymotrypsin and the pepsin ones were still functional like insulin and CWPs. This
indicates that CWPs hydrolysis by chymotrypsin and the pepsin did not impair the
biological activity of the proteins suggesting the existence of biologically active
peptides contained in such fractions.

Figure 11: CWPs activate Akt and ERK1/2 pathways in HEK293 and HepG2 cells.
HEK293 cells transiently over-expressing hIR or not, and HepG2 cells endogenously
expressing hIR showing phosphorylation of Akt and ERk1/2 on treatment with insulin
or CWPs. A) pAkt, Akt, pERK and ERK bands visualized after western blotting. B)
and C) The fold increase in phosphorylation of Akt and ERK1/2 (respectively) over
the control.
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4.3 Effects of LF on Akt and ERK1/2 pathways in HEK293 and HepG2 cells
Following this, we investigated the effects of two potential candidates in
CWPs: LF and adiponectin, on the Akt and ERK pathways. Both camel and bovine LF
potentiated an increase in the phosphorylation of ERK1/2 that seemed to increase with
over expression of hIR in HEK293 cells. However, the increase was more pronounced
by bovine LF (Figure 12). Moreover, bovine LF also induced the phosphorylation of
Akt, which was not evident when both HEK293 and HepG2 cells were treated CMLF
(Figure 12). In HepG2 cells, however, CMLF potentiated ERK phosphorylation more
than bovine LF. The results with bovine LF are consistent with previously published
research that showed that LF increases insulin induced Akt phosphorylation [79, 80].
Adiponectin did not show any activation of both pathways and was not continued with
for further investigations (data not shown).

Figure 12: Effects of LF on Akt and ERK1/2 pathways in HEK293 and HepG2 cells.
Western blotting data of cells lysates from HEK293 cells transiently over expressing
hIR or not, and HepG2 cells endogenously expressing hIR showed significant
phosphorylation of Akt and ERK1/2 when treated with CWPs, bovine milk whey
proteins (BWPs) and bovine LF. Camel LF on the other hand, showed significant
activation of ERK1/2 pathway and only very slight phosphorylation of Akt.
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4.4 Positive effects of CWP hydrolysates on Akt and ERK1/2 pathways in
HEK293 and HepG2 cells
Next, we profiled the most potent peptides obtained from pepsin hydrolysis of
the raw CWPs for their biological activity on Akt and ERK1/2 pathways. These
peptides are designated as P3:1, P5:1, P5:2, and P6:2 and used at 1 mg/ml along with
the original CWPs (1 mg/ml). This dose was selected based on dose response studies
of CWP and its hydrolysates on cells, showing maximum phosphorylation at 1mg/ml
(data not shown). Among these peptides, P3:1, P5:1, and P5:2 showed to different
extents, a stronger response on both Akt and ERK1/2, while P6:2 only induced a weak
response with a relative stronger action of the peptide fractions on ERK1/2 compared
to Akt pathway (Figure 13). Akt and ERK phosphorylation was observed in mock
HEK293 cells as well as HepG2 cells with a few differences in the effect of the
different peptide fractions in the two cell types. HEK cells overexpressing hIR
however, stimulated only ERK phosphorylation and did not show any significant
phosphorylation of Akt on treatment with the peptides (Figure 13). Together, these
observations demonstrate the biological activity of peptide fractions obtained from
pepsin hydrolysis of the whole CWPs and further confirm the existence of bioactive
peptides in CWPs.
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Figure 13: Positive effects of CWP hydrolysates on Akt and ERK1/2 pathways in
HEK293 and HepG2 cells. These western blots show the successful phosphorylation
of Akt and ERK1/2 by 3 out of the 4 peptic hydrolysates of CWP tested on mock
HEK293 cells and HepG2 cells endogenously expressing hIR. HEK293 cells over
expressing hIR showed only ERK phosphorylation.
4.5 Positive effects of CWPs and their hydrolysates on hIR activity studied by
BRET in HEK293 cells
Next, we wanted to link our data on Akt and ERK1/2 with the putative effects
of the raw CWPs and their peptide fractions on the activation of the hIR transiently
expressed in HEK293 cells. For this, we used BRET technology as previously
described. The assay measures in live cells the physical recruitment of IRS1-YFP
protein to hIR-Rluc upon its activation by insulin and camel milk fractions as described
in the methods sections (Figure 9). As a validation of the BRET assay, insulin
promoted a nice dose-dependent increase in the BRET signal between hIR-Rluc and
IRS1-YFP with the expected potency (EC50 value of 386.52± 32.34 nM, n=5) (Figure
14A). Next, we examined the effect of a single stimulation on BRET signals in cells
upon their incubation 60 minutes at 37ºC with either insulin (1 µM), CWPs (1 mg/ml),
or the different peptide fractions (1 mg/ml). As shown in Figure 14B, CWPs and their
peptide fractions clearly increased the BRET signal between hIR-Rluc and IRS1-YFP
and this to different extent (50 - 75%, p<0.001, n=5-8) compared to insulin used as a

37
positive control. These observations suggest a positive pharmacological effect of
camel milk fractions on hIR activity. To further confirm these observations, we
performed dose-response analysis showing a significant dose-dependent BRET
increase with CWPs (Figure 14C) as well as the different peptide fractions (Figure
14D). Together these results reveal positive effects of CWPs and their peptide fractions
on hIR activity suggesting either a direct or an indirect on hIR in HEK293 cells that
may explain our data on Akt and ERK1/2 pathways shown in Figure 11 and 13.

Figure 14: Positive effects of single treatments of CWPs and their hydrolysates on hIR
activity studied by BRET in HEK293 cells. BRET experiments carried out in
transfected HEK293 cells showing positive stimulation of the IR and subsequent
recruitment of IRS1. A) Dose response of insulin, B) BRET response after 1 hour
treatment of single dose of insulin (1uM), CWPs or its fractions (1mg/ml), C) Dose
response of CWPs, D) Dose response of peptic hydrolysates of CWPs.
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Figure 15: Positive effects of co-treatment of insulin with CWPs or their hydrolysates
on hIR activity studied by BRET in HEK293 cells. BRET experiments carried out in
transfected HEK293 cells showing significant increase in insulin-induced stimulation
of the IR and subsequent recruitment of IRS1. A) Co-treatment of cells with CWPs or
its hydrolysates with single dose of insulin (1µM), B) Dose response of insulin on cells
pre-treated with CWPs or its fractions, C) Dose response of CWPs, D) Dose response
of peptic hydrolysates of CWPs.

We also tested the effect of the combined stimulation of the cells co-expressing
hIR-Rluc and IRS1-YFP with insulin (1 µM) in the presence of 1 mg/ml of either
CWPs or their peptide fractions in the aim to reveal any allosteric effects on hIR. This
was based on the previous study reporting a positive allosteric action of camel milk on
hIR activity [77]. As shown in Figure 15A, the co-treatments with CWPs and their
peptide fractions significantly potentiated, to different extent (60 - 100%, p<0.001,
n=5-8), the insulin-mediated BRET signals. Such a positive effect was also confirmed
on insulin dose-response showing a significant increase in both the efficacy (Emax,
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p<0.001, n=5-8) and the potency (given in Log EC50, p<0.001, n=5) of insulin (Figure
15B) (Table 3) revealing a positive allosteric action of CWPs and their peptide
fractions on hIR. Additionally, we used the angiotensin receptor (AT1R) conjugated
to Rluc as BRET donor and its downstream signaling protein, Gαq conjugated to
Venus (a variant of YFP) as a negative control for this experiment. As shown in Figure
15C and 15D, single treatment of CWPs and its hydrolysates as well as their cotreatment with Angiotensin II (Ang II) did not significantly increase the BRET signal
compared to the control. This confirms that CWPs will not randomly potentiate any
receptor in the cell.
To demonstrate this positive allosteric action on hIR, we also examined the
effect of the co-treatment on ERK1/2 response in cells pre-treated or not with either
CWPs (1 mg/ml) or the different peptide fractions (1 mg/ml) for 60 minutes at 37ºC
before their stimulation with insulin (1 µM) for 5 minutes at 37ºC. As shown in Figure
16, the co-treatment with CWPs and the different peptide fractions strongly potentiated
the insulin-mediated ERK1/2 phosphorylation and this was consistent with our BRET
data shown in Figure 15. Together these results also reveal a positive allosteric action
of CWPs and their peptide fractions on hIR activity in addition to their insulinindependent effects.
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Figure 16: Positive effects of co-treatment of insulin with CWPs or their hydrolysates
on ERK1/2 phosphorylation in HEK293 cells. In HEK293 cells transiently over
expressing hIR A) pre-treatment of cells with CWPs and their hydrolysates for 60
minutes followed by 5 minutes with insulin and B) Co-treatment of cells with insulin
and CWPs and their hydrolysates for 5 minutes, showed increase in ERK1/2
phosphorylation to almost the levels of insulin.
4.6 The positive allosteric effect of CWPs and their peptide fractions on hIR
depends on its activation by insulin
In order to characterize the positive allosteric action of CWPs and their peptide
fractions on hIR activity, we examined the effect of the hIR-selective peptide
antagonist, S961, as previously reported [90]. For this, BRET measurements were
performed in HEK293 cells transiently co-expressing hIR-Rluc and IRS1-YFP and
treated or not with either insulin (1 µM), CWPs (1 mg/ml), or the different peptide
fractions (1 mg/ml), in the absence (control) or presence of 1 µM of S961. As shown
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in Figure 17A, the different treatments significantly elicited BRET increase between
hIR-Rluc and IRS1-YFP (p<0.001, n=3) further confirming the positive action of
CWPs and their peptide fractions on hIR activity. In addition, S961 treatment
drastically inhibited insulin-mediated BRET by∼80 % compared to the control
(p<0.0001, n=3) indicating that the increase in the BRET signal indeed reflects hIR
activation by insulin. However, S961 had no significant effects on the BRET signals
promoted by CWPs and the different peptide fractions (Figure 17A). Next, to confirm
our positive BRET data indicating the potentiation of IR, we analysed the
phosphorylation status of the IR. As we expected, IR was phosphorylated by the whey
proteins as well all the hydrolysates (Figure 18A) further supporting the suggestion
that CWPs interact directly with the hIR in some way.
In the co-treatment protocol where cells were treated with insulin in the
presence of either CWPs or the different peptide fractions, a very strong potentiation
in the BRET signals was observed compared to the control (p<0.0001, n=3) further
confirming the positive allosteric action on hIR (Figure 17B). More interestingly, the
treatment with S961 drastically abolished the potentiation of the BRET signals
(p<0.0001, n=3) (Figure 17B) and the remaining partial response reflects the direct
effects of CWPs and different peptide fractions on hIR similarly to what we obtained
in Figure 17A. Adding to this result, we also observed that co-treatment of CWPs with
insulin increased phosphorylation of hIR (Figure 18B). More importantly, this
phosphorylation was completely blocked in the presence of S961, further proving that
the increase in sensitivity to insulin observed in BRET is through the insulin receptor.
Moreover, we initially used two different pIR antibodies recognizing two
different phosphorylated tyrosines in the hIR. Interestingly, although insulin
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phosphorylated both these tyrosine residues, CWPs phosphorylated only one (i.e., Tyr
1345) indicating differential phosphorylation of the receptor by CWPs (Figure 18C).
This could be an explanation for the increase in IR potentiation when cells were pretreated with CWPs before challenging them with insulin. For all further experiments
with the hydrolysates, anti-pIR (Tyr 1345) was used.

Figure 17: The positive allosteric effect of CWPs and their peptide fractions on hIR
depends on its activation by insulin. These graphs show the differences in BRET
potentiation with A) single treatment of CWPs and its hydrolysates with and without
the hIR antagonist S961 B) co-treatment of CWPs and its hydrolysates with insulin in
the presence and absence of S961.
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Figure 18: The phosphorylation of IR showing that the positive allosteric effect of
CWPs and their peptide fractions depends on its activaion by insulin. In HEK293 cells
overexpressing hIR: A) Single treatment by insulin, CWPs or its hydrolysates results
in phosphorylation of IR. B) Pretreatment with CWPs or its hydrolysates followed by
treatment with insulin (1 uM) leads to increase in phosphorylation of IR and this is
blocked by S961. C) Differential phosphorylation of the insulin receptor by CWPs.
4.7 Positive effects of CWPs and their hydrolysates on glucose uptake in HepG2
cells
In order to translate our BRET and kinase (Akt and ERK1/2) phosphorylation
data into more integrated cell response and to make a link with the hypoglycemic
properties of camel milk demonstrated in many in vivo studies, we also examined the
effects of CWPs and different peptide fractions on glucose uptake in native/nontransfected HepG2 cells. As shown in Figure 19, unexpected in contrast to insulin all
the other treatments significantly (p<0.0001, n=5) and to different extent promoted
glucose uptake in HepG2 cells. HepG2 cells being liver cells predominantly express
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glucose transporter 2 (GLUT2), while insulin induces glucose uptake through GLUT4
[91, 92]. Glucose uptake through GLUT2 is insulin independent. Together, this could
explain the low levels of glucose uptake into insulin treated HepG2 cells.

Figure 19: Positive effects of CWPs and their hydrolysates on glucose uptake in
HepG2 cells. CWPs and its hydrolysates stimulated glucose uptake into HepG2 cells
endogenously expressing the hIR.
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Table 3: Emax and Log EC50 values determined from the different single and
combined treatments with insulin, CWPs, and the different peptide fractions (as shown
in Figure 14C and Figure 15B).
Treatment

Emax (%)

Emax (%)

Log EC50of insulin

in single

in combined

in combined

treatment

treatment

treatment

100

100

-6.28 ± 0.07 (n=5)

CWPs

80 ± 8 (n=8)

184± 18 (n=8)

-7.13 ± 0.14 (n=5)

P3:1

67 ± 13 (n=5)

183± 19 (n=5)

-7.29 ± 0.34 (n=5)

P5:1

51 ± 8 (n=8)

162 ± 17 (n=8)

-7.63 ± 0.35 (n=5)

P5:2

76 ± 16 (n=5)

188± 23 (n=5)

-7.50 ± 0.34 (n=5)

P6:2

70 ± 9 (n=8)

157± 19 (n=8)

-7.46 ± 0.39 (n=5)

Insulin
(Control)
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Chapter 5: Discussion and Conclusion
The antidiabetic nature of CM has been proved time and again by multiple in
vivo studies in both animal models of the disease and diabetic humans. As mentioned
earlier, a recent study revealed that raw CM significantly increased the recruitment of
substrate proteins involved in insulin- induced downstream signaling pathways, to the
hIR [77]. This potentiation was narrowed down to be the action of a component in the
whey fraction of CM. Due to its obviously major role in glucose homeostasis, we
hypothesized that this effect was linked to the activation of hIR by CWPs. To answer
our question, we looked into effect of CWPs on induction of different mechanisms that
are normally carried out by insulin for glucose homeostasis via the hIR:
phosphorylation Akt and ERK1/2, physical association of IRS1 to hIR and increase in
glucose uptake. The in vitro effects of CWPs, its hydrolysates, LF and adiponectin
were studied on these three parameters. CWPs and its hydrolysates clearly potentiated
Akt and ERK phosphorylation to levels that were comparable to insulin. These two
proteins play key roles in two major pathways activated by the insulin receptor, Akt in
the metabolic pathway and ERK1/2 in the mitogenic pathway. This was true even for
the peptic and chymomtryptic hydrolysates of CWP as well as the different peptide
groups obtained after peptic hydrolysis and bovine LF. CMLF however, was only seen
to activate the ERK1/2 signaling pathway, and to a lower extent than bovine LF. It is
possible that the higher activity of bovine LF when compared to CMLF is due to the
fact that bovine LF used here was commercially purchased, while CMLF was isolated
in the university labs. However, we can also speculate that CMLF when given to cells
as pure treatment does not elicit the same response as when it enters the body as part
of whole CM. As mentioned before, a number of factors like the pH and stability of
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CM along with the encapsulation of milk proteins by lipid nanoparticles, all contribute
to the better bioavailability of CM proteins once ingested [61, 67].
It’s important to note here that since the phosphorylation of Akt and ERK are
not events that are exclusive to hIR activation and is possible through other receptors,
we cannot use these results to confirm activation of hIR or the binding of CWPs and
its hydrolysates to the hIR.
Stepping one step closer to hIR activation, CWPs, its hydrolysates and LF also
showed increased BRET signals (upto 75% that of insulin) signifying the physical
association of hIR with IRS1. IRS1 is an important scaffolding protein involved in
both the metabolic Akt and mitogenic ERK pathways induced by insulin through the
hIR. It is the first intracellular protein that interacts with the hIR upon activation[14,
15]. The consequent increase in glucose uptake into HepG2 cells confirms the
intracellular translation of these signals into responses.
Excitingly, when we co-treated hIR expressing cells with insulin along with
CWPs or their hydrolysates, we witnessed a 60-100% jump in insulin induced -BRET
signals. This is consistent with the observation from the previously mentioned study
by A.O. Abdulrahman and colleagues which suggested a positive allosteric action of
CM on hIR [77]. Comparing dose response studies of insulin with and without CWPs
or its hydrolysates, we can clearly see that these proteins and peptides increase both
the potency and efficacy of insulin. Fractions of CWP increased insulin induced
recruitment of IRS1 to hIR even at saturating doses of insulin. Additionally, these
signals were higher than those achieved at saturating single doses of CWPs or their
hydrolysates. Moreover, this view was strengthened further when blocking the hIR
with the antagonist S961 significantly reduced insulin–induced BRET but had almost
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no effect on that induced by any of the CWP fractions. Blocking of IR in cells treated
with both insulin and CWPs remarkably diminished the insulin effect in the treatment
and brought them back to the single treatment levels. All of these points suggest an
allosteric mode of action of action of CWPs and their peptide fractions on hIR. The
binding of insulin to the extracellular domain of the receptor, changes and stabilizes
the conformation of the receptor in such a way that enables its intracellular kinase
domains to undergo successful autophosphorylation and initiate signaling. We know
now that the different ligands can exist for a single receptor and they can stabilize and
potentiate the receptor to different extents and/or to be selective to certain downstream
pathways [93]. In this scenario, it is possible that the allosteric binding of CWPs to the
hIR stabilizes the insulin-hIR complex in a conformation that enables better interaction
with downstream proteins, higher affinity to insulin and/or a lower dissociation rate of
the ligand-receptor complex (Figure 20). A similar model of activation of the hIR is
seen in XMetS, an allosteric antibody to the hIR [41]. These results also support the
finding by Agrawal et al. (2011) where the amount of insulin required by diabetics
considerably reduced over the course of 2 years if they were consuming camel milk
[61]. Increased potency with co-treatment of insulin with CWPs or its fractions implies
that, in the presence of CWP, a smaller quantity of insulin is required to achieve the
same effect.
It is important to note here that this allosteric effect of CWPs and its
hydrolysates is in addition to the insulin-independent effects observed initially. While
this study indeed postulates some degree of direct activation of the insulin receptor by
CWPs, we cannot rule out the possibility that CWPs also have some indirect effects
on the hIR and its related pathways. It is possible that it is potentiating downstream
signaling targets in insulin induced hIR signaling pathways via activation of other
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receptors. Another possibility is that CWPs affect completely different pathways that
contribute to glycemic control via the activation of other receptors. Receptors like
IGFR and cell surface receptors for glucagon, incretins and cytokines are some
potential receptor candidates for this cause [78] (Figure 20).
Another point to note is that in the previously mentioned study by A.O.
Abdulrahman et al. (2016), CM proteins only increased the recruitment of Grb2 to hIR
and not IRS1 [77]. On the contrary, our study shows significant potentiation through
hIR-IRS1 interaction. These differences can perhaps be reconciled by the fact that
differences in storage of the milk, lactation stage, breed and living environment of the
camels can affect the concentration of proteins in the milk [46]. Throughout the course
of this thesis work, CWPs were fractionated from fresh CM every week. Though the
source of CM was always the same farm, minimal differences were observed in Akt
and ERK phosphorylation levels and also in the IR activation levels seen in BRET
experiments with different preparations of CWPs. These differences can be attributed
to the reported changes in CM protein levels that come along with changes in seasons
and changes in lactation periods [46]. The final values and results are averages of three
or more distinct experiments.
Increasing the sensitivity of hIR via allosteric binding is an exciting possibility
that comes with the potential to provide a new door for drug development strategies
for diabetes. Studying the structural and physical properties of these interactions will
help us understand the molecular interactions associated with hIR signaling better.
Since they potentially bind to a site completely different spatially and structurally to
that of insulin, allosteric modulator’ actions can be more specific to the receptor than
that of the orthosteric ligand. This is because sequence similarity in these sites is more

50
unlikely across receptors from the same family (for example: IR and IGFR) [36].
Therapies that increase the sensitivity of the hIR can reduce the requirement for
exogenous insulin and hence, also be less likely to induce hyperinsulinemia. When
therapies like this are started at early stages of diabetes, they may even postpone or
nullify the need for exogenous insulin by preserving β cell function in the pancreas
[41].
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Figure 20 : Putative model of the action of CWPs on the IR.
A) Allosteric mode of action by direct interaction with the IR, B) Indirect effects on
IR activated pathways via another receptor (adapted from [77]).
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Chapter 6: Future Directions
This research definitely takes us one step closer to understanding the molecular
mechanisms that are responsible for the hypoglycemic effects of CM observed in vivo.
Although, it will be beneficial to investigate the action of CWPs and its hydrolysates
on other receptors involved in glucose homeostasis, such as the IGFR, glucagon and
incretin receptors. Another interesting target would be the IR-IGFR hybrid receptors,
since they respond to insulin and IGF in ways that are different to their homodimeric
counterparts. Additionally, our study prioritized only a subset of the hydrolysates
produced by CWPs on gastric digestion. Further investigations are required to assess
the effects of hydrolysates generated by different enzymes/ combinations of enzymes
in different conditions (e.g. time, pH) to bring us closer to actual stomach conditions.
It is also essential to confirm the in vitro effects of CWP hydrolysates in in
vivo systems such as diabetic mice models. In vitro studies rule out the physiological
effects of persistent high blood glucose levels in the environment. The cancerous
characteristics of established cell lines like HepG2 cells can lead to altered results [94].
These effects may very well contribute to differences in the hypoglycemic activity of
camel milk in vivo.
Finally, sequencing and studying the peptides obtained after peptic hydrolysis
of CWP is another possibility that could help us move further. Protein modeling and
binding studies of these hydrolysates can provide us with better insights into the
working and activation of the IR. Above all, it can give us a new perspective on
modulation of IR signaling.
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